Bases biológicas, patobiológicas y bioclínicas del metabolismo del surfactante pulmonar en la especie humana

Biological, pathobiological and bioclinical bases of pulmonary surfactant metabolism in the human species

Publicado 2008-09-01

Abrir | Descargar
PDF FLIP
Número
Vol. 20 Núm. 3 (2008)
Sección
Revisión de tema
Cómo citar
Bases biológicas, patobiológicas y bioclínicas del metabolismo del surfactante pulmonar en la especie humana.
rev. colomb. neumol. [Internet]. 2008 Sep. 1 [cited 2024 Nov. 22];20(3):92-106.
DOI
Licencia
Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Grégory Alfonso García
Docente Experto en Genética, Bioquímica, y Biología Celular y Molecular Humana
    Paulina Ojeda
    Patólogo. Hospital Santa Clara
      Mostrar biografía de los autores

      El síndrome de disfunción en el metabolismo del surfactante pulmonar (SMPD), clásicamente denominado Proteinosis Alveolar Pulmonar (PAP), es un desorden respiratorio inusual, caracterizado por una acumulación excesiva y abundante de proteínas y fosfolípidos derivados del surfactante en el alveolo pulmonar y en las vías aéreas distales, con anormalidades asociadas secundarias del intercambio pulmonar gaseoso, que genera insuficiencia respiratoria. Al menos tres mecanismos patofisiológicos generales pueden seguir al desarrollo de los rasgos característicos de la PAP: primario (idiopático, esencial, adquirido o adulto), secundario y congénito.

      Visitas del artículo 106 | Visitas PDF 129

      Descargas

      Los datos de descarga todavía no están disponibles.
      1. Snider GL. Only cell and molecular biology can lead to an understanding of pathogenesis of lung disease. Am J Respir Crit Care Med 2004,170:i-ii.
      2. Autores no listados. New Aspects in Pulmonary Surfactant Biology and Disease. Proceedings of the 3rd Conference in the Japanese Surfactant Molecular Pathophysiology Meetings Series, 12-13 November 2004, Osaka, Japan. Respirology 2006;11 (Suppl):S1-77.
      3. Ayadi H, Ayoub AK. Familial alveolar proteinosis. Rev Pneumol Clin 2002;58:245-8.
      4. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 2002;166:215-35.
      5. Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003;349:2527-39.
      6. Akin MR, Nguyen GK. Pulmonary alveolar proteinosis. Pathol Res Pract. 2004;200:693-8; discussion 699-700.
      7. De Blic J. Pulmonary alveolar proteinosis. Paediatr Respir Rev 2004;5:340-2.
      8. De Blic J. Pulmonary alveolar proteinosis in children. Paediatr Respir Rev 2004;5:316-22.
      9. Presneill JJ, Nakata K, Inoue Y, et al. Pulmonary alveolar proteinosis. Clin Chest Med 2004;25:593-613.
      10. Venkateshiah SB, Thomassen MJ, Kavuru MS. Pulmonary alveolar proteinosis. Clinical manifestations and optimal treatment strategies. Treat Respir Med 2004;3:217-27.
      11. Ioachimescu OC, Kavuru MS. Pulmonary alveolar proteinosis. Chron Respir Dis 2006;3:149-59.
      12. Blasco-Navalpotro MA, Guadaño-Salvadores V, Abad-Santamaría N, et al. Pulmonary alveolar proteinosis. Med Clin (Barc) 2008;131:160.
      13. Holbert JM, Costello P, Li W, et al. CT features of pulmonary alveolar proteinosis. AJR Am J Roentgenol 2001;176:1287-94.
      14. Nowers K, Rasband JD, Berges G et al. Approach to groundglass opacification of the lung. Semin Ultrasound CT MR 2002;23:302-23.
      15. Kjeldsberg KM, Oh K, Murray KA et al. Radiographic approach to multifocal consolidation. Semin Ultrasound CT MR 2002;23:288-301.
      16. Rossi SE, Erasmus JJ, Volpacchio M et al. «Crazy-paving» pattern at thin-section CT of the lungs: radiologic-pathologic overview. Radiographics 2003;23:1509-19.
      17. Pipavath S, Godwin JD. Imaging of interstitial lung disease. Clin Chest Med 2004;25:455-65.
      18. De Arriba C, Antón C, Arreche E et al. Pulmonary alveolar proteinosis and crazy paving pattern in high resolution CT. An Sist Sanit Navar 2006;29:127-30.
      19. Frazier AA, Franks TJ, Cooke EO et al. From the archives of the AFIP: pulmonary alveolar proteinosis. Radiographics 2008;28:883-99.
      20. Vrielynck S, Mamou-Mani T, Emond S et al. Diagnostic value of high-resolution CT in the evaluation of chronic infiltrative lung disease in children. AJR Am J Roentgenol 2008;191:914-20.
      21. Rosen SH, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med 1958;258:1123-42.
      22. Friedman B, Strickland CE. Pulmonary alveolar proteinosis. J Tn State Med Assoc 1958;51:507-9.
      23. Payseur CR, Konwaler BE, Hyde L. Pulmonary alveolar proteinosis; a progressive, diffuse, fatal pulmonary disease. Am Rev Tuberc 1958;78:906-15.
      24. Carabasi RJ, Barta LL. Atypical pneumonitis with interstitial fibrosis: an unusual case receiving prolonged corticosteroid therapy; pulmonary alveolar proteinosis. Dis Chest 1959;36:209-14.
      25. Katz S. Pulmonary alveolar proteinosis. GP 1959;20:165.
      26. Landis FB, Rose HD, Sternlieb RO. Pulmonary alveolar proteinosis: a case report with unusual clinical and laboratory manifestations. Am Rev Respir Dis 1959;80:249-54.
      27. Lull GF Jr, Beyer JC, Maier JG et al. Pulmonary alveolar proteinosis: report of two cases. Am J Roentgenol Radium Ther Nucl Med 1959;82:76-83.
      28. Mahaffey DE, Rush EN, Allen JD. Pulmonary alveolar proteinosis treated with varidase. J Ky Med Assoc 1959;57:1230-1.
      29. McDowell C, Williams SE, Hinds JR. Pulmonary alveolar proteinosis; report of a case. Australas Ann Med 1959;8:137-42.
      30. MoerteL CG, Woolner LB, Bernatz PE. Pulmonary alveolar proteinosis; report of case. Proc Staff Meet Mayo Clin 1959;34:152-7.
      31. Sieracki JC, Horn RC Jr, Kay S. Pulmonary alveolar proteinosis: report of three cases. Ann Intern Med 1959;51:728-39.
      32. Burbank B, Morrione TG, Cutler SS. Pulmonary alveolar proteinosis and nocardiosis. Am J Med 1960;28:1002-7.
      33. Carlson DJ, Mason EW. Pulmonary alveolar proteinosis. Diagnosis of probable case by examination of sputum. Am J Clin Pathol 1960;33:48-54
      34. Fraimow W, Cathcart RT, Kirshner JJ et al. Pulmonary alveolar proteinosis. A correlation of pathological and physiological findings in a patient followed up with serial biopsies of the lung. Am J Med 1960;28:458-67.
      35. Pitt LP. Pulmonary alveolar proteinosis. Review of the literature and report of a case. J Thorac Cardiovasc Surg 1960;39:252-7.
      36. Rosen SH. Pulmonary alveolar proteinosis. U S Armed Forces Med J 1960;11:1507-15.
      37. McLaughlin JS, Ramirez J. Pulmonary alveolar proteinosis. treatment by pulmonary segmental flooding. Am Rev Respir Dis 1964;89:745-52.
      38. IUMBM[base de datos en Internet]. London : international Union of Biochemistry and Molecular Biology;1977- [fecha de acceso 15 de octubre del 2008. Disponible en: http:// www.chem.qmul.ac.uk/iupac/jcbn/index.html#2
      39. PubMed [base de datos en Internet]. Bethesda: National Library of Medicine; 1966- [fecha de acceso 15 de octubre del 2008]. Disponible en: http://www.ncbi.nlm.nih.gov/PubMed/
      40. EMBASE [base de datos en Internet]. Holanda: Excerpta Medica Elsevier; 1974-[fecha de acceso 15 de octubre del 2008]. Disponible en: http://www.embase.com
      41. OMIM [base de datos en Internet]. Baltimore: Johns Hopkins University; 1966- [fecha de acceso 15 de octubre del 2008]. Disponible en: http://www.ncbi.nlm.nih.gov/entrez/dispomim
      42. HUGO [base de datos en Internet]. Bethesda: National Library of Medicine and others(exp.: Celera Genomics and the Sanger Center); 1989- [fecha de acceso 15 de octubre del 2008]. Disponible en: http://www.hugo-international.org/index.html
      43. Enhorning G. Surfactant in airway disease. Chest 2008;133:975-80.
      44. Halliday HL. Surfactants: past, present and future. J Perinatol. 2008 May;28 Suppl 1:S47-56.
      45. Pérez-Gil J. Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions. Biochim Biophys Acta 2008;1778:1676-95.
      46. Shijubo N, Kawabata I, Sato N et al. Clinical aspects of Clara cell 10-kDa protein/ uteroglobin (secretoglobin 1A1). Curr Pharm Des 2003;9:1139-49.
      47. Ligtenberg AJ, Veerman EC, Nieuw Amerongen AV et al. Salivary agglutinin/glycoprotein-340/DMBT1: a single molecule with variable composition and with different functions in infection, inflammation and cancer. Biol Chem 2007;388:1275-89.
      48. Haagsman HP, Hogenkamp A, van Eijk M et al. Surfactant collectins and innate immunity. Neonatology 2008;93:288-94.
      49. Bates SR, Tao JQ, Collins HL et al. Pulmonary abnormalities due to ABCA1 deficiency in mice. Am J Physiol Lung Cell Mol Physiol 2005;289:L980-9.
      50. van der Deen M, de Vries EG, Timens W et al. ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res 2005;6:59.
      51. Thomassen MJ, Barna BP, Malur AG et al. ABCG1 is deficient in alveolar macrophages of GM-CSF knockout mice and patients with pulmonary alveolar proteinosis. J Lipid Res 2007;48:2762-8.
      52. Wenzel JJ, Piehler A, Kaminski WE. ABC A-subclass proteins: gatekeepers of cellular phospho- and sphingolipid transport. Front Biosci 2007;12:3177-93.
      53. Epaud R, Feldmann D, Guillot L et al. Lung diseases associated with inherited disorders of surfactant metabolism. Arch Pediatr. 2008 Sep 18. [Epub ahead of print].
      54. Luzi P, Strayer DS. DNA binding proteins that amplify surfactant protein B gene expression: isolation and characterization. Biochem Biophys Res Commun 1995; 208: 153-160.
      55. Whitsett JA, Matsuzaki Y. Transcriptional regulation of perinatal lung maturation. Pediatr Clin North Am 2006;53:873-87,
      56. Maeda Y, Davé V, Whitsett JA. Transcriptional control of lung morphogenesis. Physiol Rev 2007;87:219-44.
      57. Yang CH, Szeliga J, Jordan J et al. Identification of the surfactant protein A receptor 210 as the unconventional myosin 18A. J Biol Chem 2005;280:34447-57.
      58. Tredano M, De Blic J, Griese M, Fournet JC, Elion J, Bahuau M. Clinical biological and genetic heterogeneity of the inborn errors of pulmonary surfactant metabolism. Clin Chem Lab Med 2001;39:90-108.
      59. Garcia CK, Raghu G. Inherited interstitial lung disease. Clin Chest Med 2004;25:421-33.
      60. Mallory GB Jr. Surfactant protein B deficiency as a prototype. Pediatr Pulmonol Suppl 2004;26:180-2.
      61. Tredano M, Griese M, Brasch F et al. Mutation of SFTPC in infantile pulmonary alveolar proteinosis with or without fibrosing lung disease. Am J Med Genet A 2004;126A:18-26.
      62. Brasch F, Griese M, Tredano M et al. Interstitial lung disease in a baby with a de novo mutation in the SFTPC gene. Eur Respir J 2004;24:30-9.
      63. Clark H, Clark LS. The genetics of neonatal respiratory disease. Semin Fetal Neonatal Med 2005;10:271-82.
      64. Stevens PA, Pettenazzo A, Brasch F et al. Nonspecific interstitial pneumonia, alveolar proteinosis, and abnormal proprotein trafficking resulting from a spontaneous mutation in the surfactant protein C gene. Pediatr Res 2005;57:89-98.
      65. Nogee LM. Genetics of pediatric interstitial lung disease. Curr Opin Pediatr 2006;18:287-92.
      66. Whitsett JA. Genetic disorders of surfactant homeostasis. Paediatr Respir Rev. 2006;7 Suppl 1:S240-2.
      67. Hamvas A, Cole FS, Nogee LM. Genetic disorders of surfactant proteins. Neonatology 2007;91:311-7.
      68. Ceruti M, Rodi G, Stella GM et al. Successful whole lung lavage in pulmonary alveolar proteinosis secondary to lysinuric protein intolerance: a case report. Orphanet J Rare Dis 2007;2:14.
      69. Dluhy RA, Shanmukh S, Leapard JB et al. Deacylated pulmonary surfactant protein SP-C transforms from alpha-helical to amyloid fibril structure via a pH-dependent mechanism: an infrared structural investigation. Biophys J 2003;85:2417-29.
      70. Johansson J. Molecular determinants for amyloid fibril formation: lessons from lung surfactant protein C. Swiss Med Wkly 2003 May;133:275-82.
      71. Gustafsson M, Thyberg J, Näslund J et al. Amyloid fibril formation by pulmonary surfactant protein C. FEBS Lett 1999;464:138-42.
      72. Gustafsson M, Griffiths WJ, Furusjö E et al. The palmitoyl groups of lung surfactant protein C reduce unfolding into a fibrillogenic intermediate. J Mol Biol 2001;310:937-50.
      73. Casals C, Johansson H, Saenz A et al. C-terminal, endoplasmic reticulum-lumenal domain of prosurfactant protein C - structural features and membrane interactions. FEBS J 2008;275:536-47.
      74. Nerelius C, Martin E, Peng S et al. Mutations linked to interstitial lung disease can abrogate anti-amyloid function of prosurfactant protein C. Biochem J 2008 Jul 22 [Epub ahead of print].
      75. Wang X, Liu F, Bewig B. Analysis of the GM-CSF and GM-CSF/IL-3/IL-5 receptor common beta chain in a patient with pulmonary alveolar proteinosis. Chin Med J (Engl) 2002;115:76-80.
      76. Kaminski WE, Piehler A, Wenzel JJ. ABC A-subfamily transporters: structure, function and disease. Biochim Biophys Acta 2006;1762:510-24.
      77. Albrecht C, Viturro E. The ABCA subfamily—gene and protein structures, functions and associated hereditary diseases. Pflugers Arch 2007;453:581-9.
      78. Shanklin DR, Mullins AC, Baldwin HS. Cerebropulmonary dysgenetic syndrome. Exp Mol Pathol 2008 May 28 [Epub ahead of print].
      79. Willemsen MA, Breedveld GJ, Wouda S et al. Brain-Thyroid Lung syndrome: a patient with a severe multi-system disorder due to a de novo mutation in the thyroid transcription factor 1 gene. Eur J Pediatr 2005;164:28-30.
      80. Ghio AJ, Churg A, Roggli VL. Ferruginous bodies: implications in the mechanism of fiber and particle toxicity. Toxicol Pathol 2004;32:643-9.
      81. Bonfield TL, Swaisgood CM, Barna BP et al. Elevated gelatinase activity in pulmonary alveolar proteinosis: role of macrophage colony stimulating factor. J Leukoc Biol 2006;79:133-9.
      82. Yoshioka Y, Ohwada A, Harada N et al Increased circulating CD16+ CD14dim monocytes in a patient with pulmonary alveolar proteinosis. Respirology 2002;7:273-9.
      83. Bonfield TL, Kavuru MS, Thomassen MJ. Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. Clin Immunol 2002;105:342-50.
      84. Costabel U, Guzman J. Pulmonary alveolar proteinosis: a new autoimmune disease. Sarcoidosis Vasc Diffuse Lung Dis 2005;22 Suppl 1:S67-73.
      85. Lin FC, Chang GD, Chern MS et al. Clinical significance of anti GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis. Thorax 2006;61:528-34.
      86. Nakata K, Kanazawa H, Watanabe M. Why does the autoantibody against granulocyte-macrophage colony stimulating factor cause lesions only in the lung? Respirology 2006;11 Suppl:S65-9.
      87. Busch T, Bercker S, Kaisers U. GM-CSF autoantibodies in pulmonary alveolar proteinosis. N Engl J Med 2007;356:2001-2.
      88. Uchida K, Beck DC, Yamamoto T et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 2007;356:567-79.
      89. Uchida K, Nakata K, Suzuki T et al. Granulocyte/macrophage colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy individuals. Blood 2008 Oct 9 [Epub ahead of print].
      90. Durán Acuña R. Fosfolipoproteinosis alveolar(10 casos 12 años de experiencia). Revista Colombiana de Neumologia 216;1: 8-13.
      91. Ramirez J, Nyka W, McLaughlin J. Pulmonary alveolar proteinosis. Diagnostic technics and observations. N Engl J Med 1963;268:165-71.
      92. Ramirez J, Schultz RB, Dutton RE. Pulmonary alveolar proteinosis: a new technique and rationale for treatment. Arch Intern Med 1963;112:419-31.
      93. Ramirez J. Pulmonary alveolar proteinosis. Biochem Clin 1964;4:165-74.
      94. Ramirez J. Pulmonary alveolar proteinosis: a roentgenologic analysis. Am J Roentgenol Radium Ther Nucl Med 1964;92:571-7.
      95. Ramirez J, Campbell GD. Pulmonary alveolar proteinosis. endobronchial treatment. Ann Intern Med 1965;63:429-41.
      96. Ramirez J, Kieffer RF Jr, Ball WC Jr. Bronchopulmonary lavage in man. Ann Intern Med 1965;63:819-28.
      97. Ramirez J. Bronchopulmonary lavage. New techniques and observations. Dis Chest 1966;50:581-8.
      98. Ramirez J, Savard EV, Hawkins JE. Biological effect of pulmonary washings from cases of alveolar proteinosis. Am Rev Respir Dis 1966;94:244-6.
      99. Ramirez J. Pulmonary alveolar proteinosis. Treatment by massive bronchopulmonary lavage. Arch Intern Med 1967;119:147-56.
      100. Hashizume T. Pulmonary alveolar proteinosis successfully treated with ambroxol. Intern Med 2002;41:1175-8.
      101. Kavuru MS, Bonfield TL, Thomassen MJ. Plasmapheresis, GM-CSF, and alveolar proteinosis. Am J Respir Crit Care Med 2003;167:10361.
      102. Cho K, Nakata K, Ariga T et al. Successful treatment of congenital pulmonary alveolar proteinosis with intravenous immunoglobulin G administration. Respirology 2006;11 Suppl:S74-7.
      103. Fukuno K, Tomonari A, Tsukada N et al. Successful cord blood transplantation for myelodysplastic syndrome resulting in resolution of pulmonary alveolar proteinosis. Bone Marrow Transplant 2006;38:581-2.
      104. Barraclough RM, Gillies AJ. Pulmonary alveolar proteinosis: a complete response to GM-CSF therapy. Thorax 2001;56:664-5.
      105. de Vega MG, Sánchez-Palencia A, Ramírez A et al. GM-CSF therapy in pulmonary alveolar proteinosis. Thorax 2002;57:837.
      106. Tazawa R, Nakata K, Inoue Y et al. Granulocyte-macrophage colony-stimulating factor inhalation therapy for patients with idiopathic pulmonary alveolar proteinosis: a pilot study; and long-term treatment with aerosolized granulocyte macrophage colony-stimulating factor: a case report. Respirology 2006;11 Suppl:S61-4.
      107. Venkateshiah SB, Yan TD, Bonfield TL et al. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. Chest 2006;130:227-37.
      108. Wylam ME, Ten R, Prakash UB et al. Aerosol granulocyte macrophage colony-stimulating factor for pulmonary alveolar proteinosis. Eur Respir J 2006;27:585-93.
      109. Poletti V, Costabel U, Casoni GL et al. Rare infiltrative lung diseases: a challenge for clinicians. Respiration 2004;71:431-43.
      110. Chung MJ, Lee KS, Franquet T et al. Metabolic lung disease: imaging and histopathologic findings. Eur J Radiol 2005;54:233-45.
      111. Juvet SC, Hwang D, Waddell TK et al. Rare lung disease II: pulmonary alveolar proteinosis. Can Respir J 2008;15:203-10.
      112. Bonfield TL, Raychaudhuri B, Malur A et al. PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor. Am J Physiol Lung Cell Mol Physiol 2003;285:L1132-6.
      113. Bonfield TL, Farver CF, Barna BP et al. Peroxisome proliferator-activated receptor-gamma is deficient in alveolar macrophages from patients with alveolar proteinosis. Am J Respir Cell Mol Biol 2003;29:677-82.
      114. Thomassen MJ, Raychaudhuri B, Bonfield TL et al. Elevated IL-10 inhibits GM-CSF synthesis in pulmonary alveolar proteinosis. Autoimmunity 2003;36:285-90.
      115. Ikegami M, Whitsett JA, Chroneos ZC et al. IL-4 increases surfactant and regulates metabolism in vivo. Am J Physiol Lung Cell Mol Physiol 2000;278:L75-80.
      116. Homer RJ, Zheng T, Chupp G et al. Pulmonary type II cell hypertrophy and pulmonary lipoproteinosis are features of chronic IL-13 exposure. Am J Physiol Lung Cell Mol Physiol 2002;283:L52-9.
      117. Bonfield TL, Barna BP, John N et al. Suppression of activin A in autoimmune lung disease associated with anti-GM-CSF. J Autoimmun 2006;26:37-41.
      118. Bonfield TL, Swaisgood CM, Barna BP et al. Elevated gelatinase activity in pulmonary alveolar proteinosis: role of macrophage-colony stimulating factor. J Leukoc Biol 2006;79:133-9.
      119. Maygarden SJ, Iacocca MV, Funkhouser WK, Novotny DB. Pulmonary alveolar proteinosis: a spectrum of cytologic, histochemical, and ultrastructural findings in bronchoalveolar lavage fluid. Diagn Cytopathol 2001;24:389-95.
      120. Costabel U, Guzman J, Bonella F, Oshimo S. Bronchoalveolar lavage in other interstitial lung diseases. Semin Respir Crit Care Med 2007;28:514-24.
      121. Mukae H, Ishimoto H, Yanagi S et al. Elevated BALF concentrations of alpha- and beta-defensins in patients with pulmonary alveolar proteinosis. Respir Med 2007;101:715-21.
      122. Nara M, Sano K, Ogawa H et al. Serum antibody against granulocyte/macrophage colony-stimulating factor and KL-6 in idiopathic pulmonary alveolar proteinosis. Tohoku J Exp Med 2006;208:349-54.
      123. Hirakata Y, Kobayashi J, Sugama Y et al. Elevation of tumour markers in serum and bronchoalveolar lavage fluid in pulmonary alveolar proteinosis. Eur Respir J 1995;8:689-96.
      124. Seymour JF, Doyle IR, Nakata K et al. Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis. Thorax 2003;58:252-7.
      125. Minakata Y, Kida Y, Nakanishi H et al. Change in cytokeratin 19 fragment level according to the severity of pulmonary alveolar proteinosis. Intern Med 2001;40:1024-7.
      126. Bonfield TL, John N, Malur A et al. Elevated monocyte chemotactic proteins 1, 2, and 3 in pulmonary alveolar proteinosis are associated with chemokine receptor suppression. Clin Immunol 2005;114:79-85

      Información

      Historia de la revista

      Palabras clave

      Código QR

      Patrocinadores

       Nos apoyan +Info Aquí 

       

      Directorios e indexadores

       

      Perfil de Google Scholar

      Más leídos en los últimos 30 días

      Número actual

      Sistema OJS 3.4.0.7 - Metabiblioteca |